华润医药(03320.HK) 公布，附属昆药集团2024年度初步业绩，营业总收入84.01亿人民币(下同)，较上年度(追溯调整后)微降0.3%。股东应占净利润6.48亿元，增长19.9%，每股盈利86分。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-10 16:25。)
| 公布日期 | 派息事项 | 派息内容 |
|---|---|---|
| 2024/08/29 | 中期业绩 | 股息：人民币 0.0830 (约相等于 0.0908 港元, 可选择港币或该等货币组合) |
| 2024/03/26 | 末期业绩 | 股息：人民币 0.1540 (约相等于 0.1697 港元, 可选择HKD或该等货币组合) |
| 2023/08/31 | 中期业绩 | 无派息 |
| 2023/03/30 | 末期业绩 | 股息：港元 0.1600 (约相等于 人民币 0.14元, 可选择以人民币收取) |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.